Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Empagliflozin + Metformin vs Synjardy in Healthy Volunteers
NCT06823856Phase 1Completed
- Sponsor
- Gedeon Richter Plc
- Start
- May 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of empagliflozin + metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Gedeon Richter Plc. Primary endpoints: Area Under the Concentration-Time Curve From Time 0 to Last Collection Time t at 7 weeks and Maximum Concentration in Plasma at 7 weeks. Started May 2025; status: completed.
02
Drugs
empagliflozin + metformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06823856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06823856.